Résumé:
These study aims to determinethe benefit use of probiotics as a preventive or curative measure
in chronic inflammatory bowel diseases (IBD) such as Crohn's disease, or ulcerative colitis.
Three articles scientists whose research themes treat the subject through in vitro, in vivo and
clinical trials. The first article of Shri Pathmakanthan and his collaborators. (2004);
demonstrates the beneficial immunomodulatory effect of Lactobacillus plantarum 299 in cells
extracted from inflamed human colon by determining the pattern of cytokine secretion
(interleukin [IL] -1b, tumor necrosis factor [TNF] -a, interferon [IFN] -g and IL-10) and their
cellular sources in mononuclear cells isolated from colonic mucosa of normal and ulcerative
colitis (UC) in response to probiotic and pathogenic bacteria. The second selected article of
Schlutz and his collaborators. (2002), determines the Lactobacillus plantarum 299Vuse in the
treatment and prevention of spontaneous colitis in interleukin-10 deficient mice, according to
four different protocols varying the times of oral administration of the probiotic bacteria
compared to colonization by SPF bacteria in IL-10 - / - mice and evaluated the effect of this
probiotic organism on immune activation of mucous membranes. The last article of Ajit Sood
his co-authors. (2009); is about a multicenter, randomized, double-blind, placebo-controlled
trial of a high potency probiotic, VSL # 3, for the treatment of mild to moderately active UC in
affected patients. The authors results approved that Lactobacillus plantarum has beneficial
immunomodulatory activity by increasing the synthesis and secretion of IL-10 in macrophages
and cells derived from the inflamed colon. This may provide a mechanism by which probiotic
bacteria enhance inappropriate inflammation and induce tolerance. Also, L. plantarum may
attenuate immune-mediated colitis and suggest a therapeutic role in chronic inflammatory
bowel disease and that the VSL # 3 probiotic complex is safe and effective in achieving clinical
responses and remissions in patients with Mild to moderately active UC.
